NCT00620815已完成2 期
A Phase II, Randomized, Placebo-controlled, Observer-blind, Multi Center Study on the Safety and Immunogenicity of Novartis Tetravalent Influenza Vaccine (Containing Both Interpandemic Strains and H5N1) in Adults Aged 18 Years and Above
Novartis Vaccines4 个研究点 分布在 1 个国家目标入组 601 人开始时间: 2007年11月最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 601
- 试验地点
- 4
- 主要终点
- To Demonstrate the Equivalence of Antibody Response Against A/H5N1 Strain Elicited by the Three Different Immunization Schedules on Day 43.
研究概览
简要总结
Evaluate the immune response and reactogenicity of H5N1 vaccination in adults aged 18 years and above (as part of a tetravalent vaccine)
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Single (Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy subjects (aged 18 years and above) who have signed an informed consent form
排除标准
- •Any acute or chronic illness
- •Receipt of seasonal influenza vaccine for the current season 2007/2008
- •Known or suspected impairment/alteration of immune function
- •Receipt of another vaccine within 3 weeks prior to Visit 1 or planned vaccination within 3 weeks following the last study vaccination
- •Any serious disease
- •Hypersensitivity to eggs, chicken protein, chicken feathers, influenza viral protein,neomycin or kanamycin or any other component of the study vaccine
- •Receipt of blood, blood products or immunoglobulins 3 months prior to vaccination
结局指标
主要结局
To Demonstrate the Equivalence of Antibody Response Against A/H5N1 Strain Elicited by the Three Different Immunization Schedules on Day 43.
时间窗: up to day 43
The antibody response was determined by SRH assay. Geometric mean areas (GMAs) and geometric mean ratios (GMRs) in the SRH assay were used to demonstrate the equivalence. The statistical analysis was done based on the GMRs.
次要结局
- Number of Subjects (Subjects ≤60 Years) With Reported Local Reactions After Second Vaccination(Up to 7 days after 2nd vaccination)
- Percentages of Subjects Achieving HI/MN ≥ 1:40 and SRH Area ≥ 25^mm2(Up to 43 days)
- Mean T-Cells Per Million Total Cells (95% CI) in Response to H5 Peptides and H5N1 Subunit(Three weeks after 1st vaccination (day 22) and three weeks after 2nd vaccination (day 43))
- Number of Subjects (Subjects ≤ 60 Years) With Reported Local Reactions After First Vaccination(Up to 7 days after 1st vaccination)
- Percentages of Subjects Achieving Seroconversion/Significant Increase in Antibody Titre/ Area as Measured by SRH and (HI) and at Least 4 Fold Rise in Titres by Micro-neutralization (MN) Assay-H5N1 Strain(up to day 43)
- Antibody Response Determined by HI and MN Assay.(Up to 43 days)
- Number of Subjects (Subjects ≤ 60 Years) With Reported Systemic Reactions After 1st and 2nd Vaccinations.(7 days after 1st and 2nd vaccinations each)
- Percentages of B-cell Antibodies Against H5N1 and H1N1 After Each Vaccination.(Three weeks after first vaccination (day 22) and three weeks after second vaccination (day 43))
研究者
研究点 (4)
Loading locations...
相似试验
已完成
3 期
Safety and Immunogenicity of Two Doses of aH5N1 Vaccine in Adult and Elderly Subjects With and Without Underlying Medical ConditionsInfluenza, HumanNCT02091908Seqirus540
已完成
3 期
Safety and Immunogenicity of Two Doses of aH5N1 Vaccine in Adult and Elderly Subjects With and Without Immunosuppressive Conditions *aH5N1:Monovalent H5N1 Influenza VaccineInfluenza, HumanFlu, HumanFlu, AvianInfluenza A Virus, H5N1 SubtypeInfluenzaNCT02107807Seqirus539
已完成
2 期
Immunogenicity, Safety and Tolerability of Two Doses of a Pre-pandemic Influenza Vaccine in Participants Aged 6 Months to 17 YearsProphylaxis of Avian InfluenzaNCT00537524Novartis Vaccines471
已完成
2 期
Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Adults Unprimed and Primed With Adjuvanted or Non-adjuvanted Influenza VaccinesProphylaxis of Avian Influenza VaccineNCT00478816Novartis Vaccines58
已完成
1 期
Safety and Immunogenicity Of A Recombinant H5N1 Vaccine In AdultsHealthyNCT01250795Fraunhofer, Center for Molecular Biotechnology100